PMID- 34281221
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 13
DP  - 2021 Jul 2
TI  - Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
LID - 10.3390/ijms22137170 [doi]
LID - 7170
AB  - Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new 
      class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 
      inhibitors reduce glucose reabsorption through renal systems, thus improving 
      glycemic control in all stages of diabetes mellitus, independent of insulin. This 
      class of drugs has the advantages of no clinically relevant hypoglycemia and 
      working in synergy when combined with currently available anti-diabetic drugs. 
      While improving sugar level control in these patients, SGLT2 inhibitors also have 
      the advantages of blood-pressure improvement and bodyweight reduction, with 
      potential cardiac and renal protection. In randomized control trials for patients 
      with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal 
      outcomes, but also hospitalization for heart failure, with this effect extending 
      to those without diabetes mellitus. Recently, dynamic communication between 
      autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in 
      response to SGLT2 inhibitors that may serve as a potential treatment strategy for 
      heart failure was discovered. In this review, the background molecular pathways 
      leading to the clinical benefits are examined in this new class of anti-diabetic 
      drugs, the SGLT2 inhibitors.
FAU - Wu, Victor Chien-Chia
AU  - Wu VC
AUID- ORCID: 0000-0002-9918-4369
AD  - Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, 
      Taoyuan City 33305, Taiwan.
AD  - School of Medicine, College of Medicine, Chang Gung University, Taoyuan City 
      33302, Taiwan.
FAU - Li, Yan-Rong
AU  - Li YR
AUID- ORCID: 0000-0002-0206-3473
AD  - School of Medicine, College of Medicine, Chang Gung University, Taoyuan City 
      33302, Taiwan.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Linkou 
      Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan.
FAU - Wang, Chao-Yung
AU  - Wang CY
AD  - Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, 
      Taoyuan City 33305, Taiwan.
AD  - School of Medicine, College of Medicine, Chang Gung University, Taoyuan City 
      33302, Taiwan.
AD  - Institute of Cellular and System Medicine, National Health Research Institutes, 
      Zhunan 35053, Taiwan.
AD  - Department of Medical Science, National Tsing Hua University, Hsinchu 30013, 
      Taiwan.
LA  - eng
GR  - NHRI-EX106-10617SI, NHRI-110A1-CSCO-17212418/National Health Research Institutes/
GR  - 105-2628-B-182-009-MY4 and 109-2314-B-182-070-MY3/National Science Council/
GR  - CMRPG3H0133, CMRPG3I0322, CMRPG3H0843, and CORPG3K0011/Chang Gung Memorial 
      Hospital/
PT  - Journal Article
PT  - Review
DEP - 20210702
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cardiotonic Agents/pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Heart Diseases/*prevention & control
MH  - Humans
MH  - Sodium-Glucose Transporter 2 Inhibitors/*pharmacology/*therapeutic use
PMC - PMC8268177
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - autophagy
OT  - cardiac protection
OT  - innate immunity
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/21 06:00
MHDA- 2021/08/07 06:00
PMCR- 2021/07/02
CRDT- 2021/07/20 01:03
PHST- 2021/05/01 00:00 [received]
PHST- 2021/06/12 00:00 [revised]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/20 01:03 [entrez]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2021/07/02 00:00 [pmc-release]
AID - ijms22137170 [pii]
AID - ijms-22-07170 [pii]
AID - 10.3390/ijms22137170 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Jul 2;22(13):7170. doi: 10.3390/ijms22137170.